News

Imfinzi Bladder Combo Wins FDA Priority Review

+2

Health

Imfinzi Bladder Combo Wins FDA Priority Review

Priya Raman · 2026-09-25T13:20:36.257Z

This combo looks like it could help a lot of patients who skip cisplatin, especially with those survival gains from the trial.

10 sourcesUpdated Sep 25, 20261 min read

+2

Imfinzi Bladder Combo Wins FDA Priority Review — © IJR

Sponsored

The FDA has accepted AstraZeneca's application and granted Priority Review for IMFINZI plus enfortumab vedotin in muscle-invasive bladder cancer patients who cannot take or have declined cisplatin chemotherapy. A decision is expected in the fourth quarter of 2026. The filing rests on a Phase III VOLGA interim analysis that found statistically significant, clinically meaningful improvements in event-free survival and overall survival (time without recurrence or death, and total survival time) compared with radical cystectomy with or without approved follow-up treatment. Safety matched the known profiles of each drug; no new signals were seen. Susan Galbraith of AstraZeneca said the review reinforces IMFINZI's potential to become the immunotherapy backbone in this setting and, if approved, would be the first perioperative regimen with enfortumab vedotin given only before surgery, offering "practice-changing efficacy and tolerability." Roughly one in four bladder-cancer patients develop muscle-invasive disease, and up to half are ineligible for standard cisplatin regimens, leaving surgery as the main option while recurrence stays common. IMFINZI already holds related bladder-cancer approvals; EU, Japan and other regulators are reviewing the same data, with full trial results still to come.

Sponsored

In this story:AstraZenecaUnited States Food and Drug Administrationdurvalumabenfortumab vedotin

Where do you stand?

AstraZeneca

United States Food and Drug Administration

durvalumab

Sponsored

How it spread

Broke news.cision.com · Sep 25, 2:01 AM ETCenter within the hour10 sources +6h on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

Coverage

Sponsored

Comments (2)

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Maya Lindstrom⚡7Sep 25, 2026
Priority review makes sense here but the 2026 decision date still leaves people waiting too long for access.
Priya Raman⚡8Sep 25, 2026
This combo looks like it could help a lot of patients who skip cisplatin, especially with those survival gains from the trial.

Sponsored

More on this story

Back to News

Health

FDA approves first generic twice-yearly HIV-prevention shot

FDA approved the first generic of twice-yearly HIV-prevention shot lenacapavir at about $40 a year for 120 resource-limited countries; U.S. brand lists at $28,218.

18 sources

Health

FDA grants uniQure Huntington’s gene therapy priority review

The FDA accepted uniQure’s application for priority review of its experimental Huntington’s disease gene therapy, setting a May 1, 2027, decision target and tentatively planning an advisory committee meeting. The application seeks accelerated approval based on clinical data compared with an external control; acceptance is not approval, and a confirmatory trial is planned.

8 sources

Sponsored

Health

FDA Proposes First Formula Nutrient Update in Decades

The FDA has proposed the first major update to U.S. infant-formula nutrition standards in nearly 30 years, revising requirements for vitamins A and D, iodine and manganese while seeking input on whether to require ingredients such as DHA, ARA and L-carnitine. The proposal also includes labeling changes; the agency said most tested formula samples had low or undetectable chemical contaminants and plans further reviews before issuing a final rule.

22 sources